Control | +Rifampicin 1 mg/kg | +Rifampicin 3 mg/kg | +Rifampicin 10 mg/kg | +Rifampicin 30 mg/kg | |
---|---|---|---|---|---|
Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | |
Pitavastatin | |||||
CL (ml/min/kg) | 18.0 ± 4.6 | 15.0 ± 2.5 | 7.5 ± 2.0 | 4.9 ± 1.3 | 4.3 ± 1.6 |
Fold change | 0.83 | 0.42** | 0.27** | 0.24** | |
Vdss (l/kg) | 1.79 ± 0.72 | 1.97 ± 0.50 | 0.47 ± 0.20 | 0.52 ± 0.16 | 0.55 ± 0.20 |
Fold change | 1.10 | 0.26** | 0.29** | 0.30** | |
t1/2 (h) | 5.9 ± 0.9 | 7.2 ± 1.7 | 2.9 ± 1.9 | 3.8 ± 0.7 | 4.5 ± 0.6 |
Fold change | 1.21 | 0.50** | 0.63 | 0.76 | |
Oral AUClast (ng.h/ml) | 299 ± 146 | 515 ± 417 | 2690 ± 2710 | 4070 ± 4357 | 5808 ± 4579 |
Fold change | 1.72 | 8.99** | 13.60** | 19.41** | |
Oral Cmax (ng/ml) | 225 ± 200 | 520 ± 822 | 2730 ± 2040 | 1920 ± 2950 | 2780 ± 3166 |
Fold change | 2.31 | 12.13** | 8.53** | 12.36** | |
Rosuvastatin | |||||
CL (ml/min/kg) | 27.5 ± 7.8 | 23.6 ± 2.4 | 20.0 ± 2.1 | 15.6 ± 1.9 | 13.4 ± 3.7 |
Fold change | 0.86 | 0.73 | 0.57** | 0.49** | |
Vdss (l/kg) | 0.67 ± 0.41 | 0.61 ± 0.06 | 0.64 ± 0.16 | 0.71 ± 0.08 | 0.79 ± 0.16 |
Fold change | 0.91 | 0.96 | 1.05 | 1.17 | |
t1/2 (h) | 2.5 ± 0.7 | 2.5 ± 0.8 | 2.1 ± 0.3 | 3.1 ± 0.1 | 4.8 ± 2.0 |
Fold change | 1.01 | 0.86 | 1.23 | 1.93* | |
Oral AUClast (ng.h/ml) | 49 ± 12 | 63 ± 28 | 232 ± 43 | 467 ± 267 | 744 ± 512 |
Fold change | 1.28 | 4.68** | 9.41** | 15.01** | |
Oral Cmax (ng/ml) | 15 ± 11 | 24 ± 29 | 122 ± 46 | 150 ± 100 | 227 ± 169 |
Fold change | 1.54 | 7.72** | 9.49** | 14.37** | |
Rifampicin | |||||
Oral AUClast (ng.h/ml) | 985 ± 396 | 11,300 ± 3260 | 70,100 ± 10,800 | 240,000 ± 73,900 | |
Dose-normalized change related to 1 mg/kg | — | 3.8 | 7.1 | 8.1 | |
Oral Cmax (ng/ml) | 176 ± 99 | 2050 ± 245 | 7980 ± 2480 | 24,200 ± 14,100 | |
Dose-normalized change related to 1 mg/kg | — | 3.8 | 4.5 | 4.6 |
Data represent mean ± S.D. (N = 4). One-way analysis of variance with Dunnett’s multiple comparisons test was employed to test significance with *p < 0.05; **p < 0.01.